Institute Clinic of Gynecology, Obstetrics, and Neonatology, Hospital Clínic - Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Gynecol Endocrinol. 2021 Sep;37(9):831-835. doi: 10.1080/09513590.2021.1929152. Epub 2021 May 28.
The use of ulipristal acetate (UPA) was indicated for the treatment of uterine fibroids. Following UPA suspension in March 2020, some patients presented worsening and required surgery. We aimed to identify patients at high-risk for undergoing surgery after UPA suspension.
We evaluated 85 women receiving intermittent UPA treatment until March 2020. Following UPA suspension, patients received other medical treatments or surgery. The clinico-pathological features were recoded and a quality of life health survey was completed by patients at the time of UPA suspension and at 6-months thereafter.
After the suspension of UPA, 17 of the 85 patients receiving intermittent UPA (20%) required surgery, and 68 (80%) required other medical treatments. Patients who underwent surgery were younger and had greater fibroid volume.
In our series, 20% of clinically stable patients receiving intermittent UPA required surgery following UPA suspension. These women should be considered for future medical strategies.
醋酸乌利司他（UPA）被用于治疗子宫肌瘤。2020 年 3 月 UPA 暂停使用后，一些患者的病情恶化，需要手术。我们旨在确定 UPA 暂停使用后需要手术的高风险患者。
我们评估了 85 名接受间歇性 UPA 治疗的女性，直至 2020 年 3 月。UPA 暂停使用后，患者接受了其他药物治疗或手术。记录临床病理特征，并在 UPA 暂停时和之后 6 个月由患者完成生活质量健康调查。
在 UPA 暂停后，85 名接受间歇性 UPA 治疗的患者中有 17 名（20%）需要手术，68 名（80%）需要其他药物治疗。接受手术的患者更年轻，肌瘤体积更大。
在我们的研究中，20%接受间歇性 UPA 治疗的临床稳定患者在 UPA 暂停后需要手术。这些女性应考虑未来的医疗策略。
